Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

BACKGROUND AND OBJECTIVES Kidney involvement in Waldenström macroglobulinemia is less well described compared with kidney manifestations in multiple myeloma. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Of the 1363 patients seen with Waldenström macroglobulinemia and other IgM-secreting B cell lymphoproliferative disorders seen at the Mayo Clinic between 1996 and 2015, 57 kidney biopsies were retrospectively studied. The biopsy findings were correlated with clinical, kidney, and hematologic characteristics. Criteria for inclusion were evidence of a monoclonal IgM protein and availability of a kidney and a bone marrow biopsy for review. Glomerular and tubulointerstitial pathologies were categorized according to whether they were related to the monoclonal IgM. RESULTS Of the 57 patients identified, monoclonal gammopathy-related kidney lesions were identified in 82% (47 of 57 biopsies), whereas nonmonoclonal gammopathy-related kidney lesions were seen in 18% (ten of 57). Monoclonal gammopathy-related kidney lesions included monoclonal Ig-related amyloidosis (n=19; 33%), nonamyloid glomerulopathy (n=20, 35%), and tubulointerstitial nephropathies (n=8; 14%). The most common monoclonal gammopathy-related kidney lesion was monoclonal Ig-related amyloidosis (n=19; 33%) followed by cryoglobulinemic GN (n=13; 28%). Lymphoma infiltration was the most common tubulointerstitial lesion (n=4; 9%). The hematologic diagnosis was Waldenström macroglobulinemia in 74% (n=42), monoclonal gammopathy of renal significance in 16% (n=9), and marginal zone lymphoma (n=2), chronic lymphocytic leukemia (n=2), and low-grade B cell lymphoma (n=2) in 4% each. CONCLUSIONS Our study confirms a diverse variety of kidney lesions in patients with monoclonal IgM gammopathy.

[1]  F. Petitprez,et al.  Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. , 2017, Blood.

[2]  A. Mallett,et al.  Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome , 2017, Nephrology.

[3]  F. Cosio,et al.  Outcomes of patients with renal monoclonal immunoglobulin deposition disease , 2016, American journal of hematology.

[4]  M. Kersten,et al.  Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes , 2016, British journal of haematology.

[5]  J. Goujon,et al.  Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  E. Kimby,et al.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.

[7]  I. Ghobrial Are you sure this is Waldenstrom macroglobulinemia? , 2012, Hematology. American Society of Hematology. Education Program.

[8]  A. Dispenzieri,et al.  Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. , 2012, Blood.

[9]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Dispenzieri,et al.  IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia , 2010, American journal of hematology.

[11]  T. Habermann,et al.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. , 2010, Mayo Clinic proceedings.

[12]  Benjamin Deroure,et al.  Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[13]  M. Dimopoulos,et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[14]  J. Fraumeni,et al.  Waldenström's macroglobulinemia , 1998, Cancer.

[15]  P. Verroust,et al.  Pathology of the kidney in Waldenström's macroglobulinemia. Study of sixteen cases. , 1970, The New England journal of medicine.

[16]  B. Knebelmann,et al.  Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients , 2017, Leukemia.

[17]  M. Kersten,et al.  Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia. , 2013, The Netherlands journal of medicine.

[18]  S. Yamasaki,et al.  Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren’s syndrome complicated with IgM monoclonal gammopathy of undetermined significance , 2010, Rheumatology International.